Dashboard
Manage Tickers

ONCYONCOLYTICS BIOTECH INC

Nasdaq oncolyticsbiotech.com


$ 1.10 $ 0.01 (0.92 %)    

Monday, 29-Apr-2024 09:57:28 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 432.32 $ -0.83 (-0.19 %)
DIA $ 383.24 $ 0.05 (0.01 %)
SPY $ 509.99 $ -0.23 (-0.05 %)
TLT $ 88.82 $ 0.16 (0.18 %)
GLD $ 216.49 $ 0.44 (0.2 %)
$ 1.09
$ 1.10
$ 1.11 x 400
$ 1.12 x 400
$ 1.10 - $ 1.10
$ 0.88 - $ 3.39
219,161
na
81.12M
$ 1.35
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

oncolytics-reports-acceptance-of-two-abstracts-at-the-2024-american-society-of-clinical-oncology-annual-meeting
Oncolytics Reports Acceptance Of Two Abstr...
04/25/2024 11:24:30

oncolytics-biotech-has-submitted-type-c-meeting-request-to-fda-for-q2-2024-to-discuss-the-companys-planned-registration-enabling-trial-for-pelareorep-in-hrher2--metastatic-breast-cancer
Oncolytics Biotech Has Submitted Type C Me...
04/11/2024 11:20:02

oncolytics-biotech-reports-submission-of-a-type-c-meeting-request-to-fda
Oncolytics Biotech Reports Submission Of A...
04/11/2024 11:05:43

This meeting aims to discuss the company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breas...

raymond-james-initiates-coverage-on-oncolytics-biotech-with-outperform-rating-announces-price-target-of-3
Raymond James Initiates Coverage On Oncoly...
04/04/2024 17:47:05

Raymond James analyst Rahul Sarugaser initiates coverage on Oncolytics Biotech (NASDAQ:ONCY) with a Outperform rating and an...

hc-wainwright--co-maintains-buy-on-oncolytics-biotech-maintains-5-price-target
HC Wainwright & Co. Maintains Buy on Oncol...
03/08/2024 18:04:15

HC Wainwright & Co. analyst Patrick Trucchio maintains Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $5 pric...

recap-oncolytics-biotech-q4-earnings
Recap: Oncolytics Biotech Q4 Earnings
03/07/2024 21:10:12

oncolytics-biotech-q4-eps-004-beats-011-estimate
Oncolytics Biotech Q4 EPS $(0.04) Beats $(...
03/07/2024 21:07:12

Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(...

earnings-scheduled-for-march-7-2024
Earnings Scheduled For March 7, 2024
03/07/2024 09:49:44

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...

a-preview-of-oncolytics-biotechs-earnings
A Preview Of Oncolytics Biotech's Earnings
03/06/2024 19:02:23

oncolytics-biotech-submits-amendment-to-goblet-to-initiate-new-phase-12-cohort-evaluating-pelareorep-in-combination-with-modified-folfirinox-with-and-without-tecentriq
Oncolytics Biotech Submits Amendment To GO...
03/05/2024 12:10:19

hc-wainwright--co-reiterates-buy-on-oncolytics-biotech-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Onco...
02/14/2024 18:45:21

HC Wainwright & Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $5 pri...

hc-wainwright--co-reiterates-buy-on-oncolytics-biotech-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Onco...
01/19/2024 12:02:44

HC Wainwright & Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $5 pri...

hc-wainwright--co-reiterates-buy-on-oncolytics-biotech-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Onco...
01/04/2024 15:26:16

HC Wainwright & Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $5 pri...

oncolytics-biotech-says-it-expects-to-initiate-first-phase-3-study-for-pelareorep-in-pancreatic-cancer-this-year-company-will-provide-guidance-on-registration-path-for-metastatic-breast-cancer-in-first-half-of-2024
Oncolytics Biotech Says It Expects To Init...
01/04/2024 12:08:10

oncolytics-biotech-presented-additional-translational-data-from-the-aware-1-breast-cancer-window-of-opportunity-study-done-in-combination-with-solti-innovative-cancer-research
Oncolytics Biotech Presented Additional Tr...
12/07/2023 12:04:23

hc-wainwright--co-maintains-buy-on-oncolytics-biotech-lowers-price-target-to-5
HC Wainwright & Co. Maintains Buy on Oncol...
11/13/2023 16:16:09

HC Wainwright & Co. analyst Patrick Trucchio maintains Oncolytics Biotech (NASDAQ:ONCY) with a Buy and lowers the price ...

oncolytics-provides-update-on-pancreatic-cancer-program-for-pelareorep-updated-plan-follows-pancans-re-evaluation-of-precision-promise-program
Oncolytics Provides Update on Pancreatic C...
11/09/2023 11:35:43

Oncolytics and its collaborator, The Pancreatic Cancer Action Network (PanCAN), had previously planned to initiate a Phase 3 tr...

earnings-scheduled-for-november-3-2023
Earnings Scheduled For November 3, 2023
11/03/2023 11:12:01

Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per ...

oncolytics-biotech-q3-eps-loss-widens-to-010
Oncolytics Biotech Q3 EPS Loss Widens To $...
11/03/2023 11:04:13

oncolytics-biotechs-earnings-outlook
Oncolytics Biotech's Earnings Outlook
11/02/2023 19:01:01

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION